JP7097027B2 - 自己免疫疾患の処置及び予防のための代謝物 - Google Patents

自己免疫疾患の処置及び予防のための代謝物 Download PDF

Info

Publication number
JP7097027B2
JP7097027B2 JP2019507125A JP2019507125A JP7097027B2 JP 7097027 B2 JP7097027 B2 JP 7097027B2 JP 2019507125 A JP2019507125 A JP 2019507125A JP 2019507125 A JP2019507125 A JP 2019507125A JP 7097027 B2 JP7097027 B2 JP 7097027B2
Authority
JP
Japan
Prior art keywords
acid
individual
mice
cells
nod
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019507125A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527714A (ja
JP2019527714A5 (enExample
Inventor
レイ マッケイ、チャールス
マリノ モレノ、エリアナ
ロケット、トレヴァー
クラーク、ジュリー
トッピング、デイヴィッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commonwealth Scientific and Industrial Research Organization CSIRO
Monash University
Original Assignee
Commonwealth Scientific and Industrial Research Organization CSIRO
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016903143A external-priority patent/AU2016903143A0/en
Application filed by Commonwealth Scientific and Industrial Research Organization CSIRO, Monash University filed Critical Commonwealth Scientific and Industrial Research Organization CSIRO
Publication of JP2019527714A publication Critical patent/JP2019527714A/ja
Publication of JP2019527714A5 publication Critical patent/JP2019527714A5/ja
Application granted granted Critical
Publication of JP7097027B2 publication Critical patent/JP7097027B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Pediatric Medicine (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019507125A 2016-08-10 2017-08-10 自己免疫疾患の処置及び予防のための代謝物 Active JP7097027B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016903143A AU2016903143A0 (en) 2016-08-10 Metabolites for treatment of autoimmune disease
AU2016903143 2016-08-10
PCT/AU2017/050845 WO2018027274A1 (en) 2016-08-10 2017-08-10 Metabolites for treatment and prevention of autoimmune disease

Publications (3)

Publication Number Publication Date
JP2019527714A JP2019527714A (ja) 2019-10-03
JP2019527714A5 JP2019527714A5 (enExample) 2020-10-22
JP7097027B2 true JP7097027B2 (ja) 2022-07-07

Family

ID=61160999

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019507125A Active JP7097027B2 (ja) 2016-08-10 2017-08-10 自己免疫疾患の処置及び予防のための代謝物

Country Status (8)

Country Link
US (3) US20190167615A1 (enExample)
EP (1) EP3496708B1 (enExample)
JP (1) JP7097027B2 (enExample)
CN (1) CN109562088A (enExample)
AU (1) AU2017310263B2 (enExample)
CA (1) CA3070939A1 (enExample)
ES (1) ES3029611T3 (enExample)
WO (1) WO2018027274A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11065217B2 (en) 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
AU2019358875B2 (en) * 2018-10-09 2025-08-21 Monash University Combination therapy for treatment and prevention of autoimmune and inflammatory diseases
CN109771404A (zh) * 2019-02-28 2019-05-21 北京大学人民医院(北京大学第二临床医学院) 丁酸在制备预防和/或治疗自身免疫性疾病药物中的应用
EP3838283A1 (en) * 2019-12-18 2021-06-23 Mundus Sanus GmbH & Co. KG Composition for use in the treatment of provocative diseases
US20230190942A1 (en) * 2020-06-03 2023-06-22 Corn Products Development, Inc. Compositions of tri-substituted starch and methods for making and using the same
CN115068458B (zh) * 2022-07-21 2023-12-12 哈尔滨医科大学 戊酸在制备防治糖尿病药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509999A (ja) 2005-09-28 2009-03-12 ズートツッカー アクチェンゲゼルシャフト マンハイム／オクセンフルト 炭水化物および炭水化物ポリオールの酪酸エステル
WO2015066433A1 (en) 2013-10-31 2015-05-07 Sloan-Kettering Institute For Cancer Research Methods and compositions for inducing regulatory t-cell generation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039703A (en) * 1989-11-16 1991-08-13 Breuer Richard I Method for treating inflammatory bowel disorders
US5840860A (en) 1993-11-17 1998-11-24 Commonwealth Scientific And Industrial Research Organization Fatty acid delivery system comprising a hydrolyzable bond
AUPQ132599A0 (en) 1999-07-01 1999-07-22 Commonwealth Scientific And Industrial Research Organisation Nasogastric enteral formulations
WO2014145970A1 (en) * 2013-03-15 2014-09-18 President And Fellows Of Harvard College Modulation of regulatory t cells via g-coupled protein receptor 43
US10226443B2 (en) * 2014-10-16 2019-03-12 New York University Methods for treating psoriatic arthritis
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US11065217B2 (en) * 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
AU2019358875B2 (en) * 2018-10-09 2025-08-21 Monash University Combination therapy for treatment and prevention of autoimmune and inflammatory diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509999A (ja) 2005-09-28 2009-03-12 ズートツッカー アクチェンゲゼルシャフト マンハイム／オクセンフルト 炭水化物および炭水化物ポリオールの酪酸エステル
WO2015066433A1 (en) 2013-10-31 2015-05-07 Sloan-Kettering Institute For Cancer Research Methods and compositions for inducing regulatory t-cell generation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Microbial Ecology in Health and Disease，2008年，20，p.103-108

Also Published As

Publication number Publication date
JP2019527714A (ja) 2019-10-03
EP3496708C0 (en) 2025-03-26
AU2017310263A1 (en) 2019-02-07
WO2018027274A1 (en) 2018-02-15
ES3029611T3 (en) 2025-06-27
EP3496708A4 (en) 2020-04-01
CA3070939A1 (en) 2018-02-15
US20190167615A1 (en) 2019-06-06
US20210244692A1 (en) 2021-08-12
EP3496708B1 (en) 2025-03-26
EP3496708A1 (en) 2019-06-19
US20250295617A1 (en) 2025-09-25
CN109562088A (zh) 2019-04-02
AU2017310263B2 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
US20250295617A1 (en) Metabolites for treatment and prevention of autoimmune disease
Jamwal et al. Intestinal epithelial expression of MHCII determines severity of chemical, T-cell–induced, and infectious colitis in mice
Sobczak et al. Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases
DeGruttola et al. Current understanding of dysbiosis in disease in human and animal models
Janowitz et al. The role of the fecal stream in Crohn's disease: an historical and analytic review
Peters et al. Innate lymphoid cells in inflammatory bowel diseases
Kim et al. Lactobacillus plantarum CBT LP3 ameliorates colitis via modulating T cells in mice
CN110049760A (zh) 用于治疗炎性疾病的组合物及其用途以及益生菌组合物
CN108883140A (zh) 治疗1型糖尿病的组合物和方法
JP2018532779A (ja) 糖尿病及び腸疾患の治療又は予防における使用のためのフィーカリバクテリウムプラウスニッツィ及びデスルホビブリオピゲル
CN107206030B (zh) 包含生酸拟杆菌作为有效成分的用于预防或治疗代谢性疾病的药学组合物
US20240024382A1 (en) Method and System to Modify an Individual's Gut-Brain Axis to Provide Neurocognitive Protection
FR2962045A1 (fr) Complexe macromoleculaire d'origine bacterienne et utilisation dudit complexe moleculaire pour prevenir et traiter les rhumatismes inflammatoires
JP2021118687A (ja) 新規のビフィドバクテリウムビフィダム菌株及び菌株由来多糖体
Hu et al. Intestinal immune imbalance is an alarm in the development of IBD
US20220202866A1 (en) Milk derived extracellular vesicles for use in treating inflammatory bowel disease
Jena et al. Influence of gut microbiota on inflammation and pathogenesis of sugar rich diet induced diabetes
AU2019358875B2 (en) Combination therapy for treatment and prevention of autoimmune and inflammatory diseases
Hume et al. The pathogenesis of Crohn's disease in the 21st century
Ohno Gut microbial short-chain fatty acids in host defense and immune regulation
Florio et al. Discovering the Nutrition-Microbiota Interplay in Inflammatory Bowel Disease: Are We There Yet?
JP2025153503A (ja) 糞便細菌叢を含む医薬組成物
Shahbazi Manipulation of Gut Microbiota during Critical Windows of Development and its Effects on Immune System Function Later in Life
Ababio et al. Inflammatory bowel disease: pathogenetic mechanisms
Sarosiek et al. Profound Improvement in Nutritional Status in Patients With Severe Gastroparesis After Receiving Enterra Therpy for up to 10 Years

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200807

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200909

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220517

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220615

R150 Certificate of patent or registration of utility model

Ref document number: 7097027

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250